Seattle Genetics, Inc. (NASDAQ:SGEN) insider Clay B. Siegall sold 18,832 shares of the business’s stock in a transaction on Thursday, January 11th. The shares were sold at an average price of $51.71, for a total transaction of $973,802.72. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

Clay B. Siegall also recently made the following trade(s):

  • On Monday, December 11th, Clay B. Siegall sold 18,832 shares of Seattle Genetics stock. The stock was sold at an average price of $55.40, for a total transaction of $1,043,292.80.
  • On Friday, November 10th, Clay B. Siegall sold 18,832 shares of Seattle Genetics stock. The stock was sold at an average price of $58.00, for a total transaction of $1,092,256.00.

Seattle Genetics, Inc. (NASDAQ:SGEN) traded down $1.41 during midday trading on Tuesday, hitting $50.95. 944,500 shares of the stock traded hands, compared to its average volume of 866,980. Seattle Genetics, Inc. has a 12-month low of $45.31 and a 12-month high of $71.32. The company has a market cap of $7,380.00, a price-to-earnings ratio of -58.56 and a beta of 2.37.

Seattle Genetics (NASDAQ:SGEN) last posted its earnings results on Thursday, October 26th. The biotechnology company reported ($0.19) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.42) by $0.23. Seattle Genetics had a negative net margin of 26.53% and a negative return on equity of 32.41%. The firm had revenue of $135.29 million during the quarter, compared to analyst estimates of $112.76 million. During the same quarter in the prior year, the business posted ($0.23) EPS. The business’s revenue was up 27.3% compared to the same quarter last year. analysts forecast that Seattle Genetics, Inc. will post -0.93 earnings per share for the current fiscal year.

Several hedge funds and other institutional investors have recently bought and sold shares of SGEN. Manning & Napier Advisors LLC bought a new stake in shares of Seattle Genetics in the 3rd quarter worth $140,098,000. Capital International Investors grew its stake in shares of Seattle Genetics by 63.7% in the 3rd quarter. Capital International Investors now owns 4,460,246 shares of the biotechnology company’s stock worth $242,682,000 after acquiring an additional 1,735,657 shares in the last quarter. Janus Henderson Group PLC grew its stake in shares of Seattle Genetics by 8,672.2% in the 2nd quarter. Janus Henderson Group PLC now owns 704,673 shares of the biotechnology company’s stock worth $36,460,000 after acquiring an additional 696,640 shares in the last quarter. Pictet Asset Management Ltd. grew its stake in shares of Seattle Genetics by 79.3% in the 3rd quarter. Pictet Asset Management Ltd. now owns 1,266,426 shares of the biotechnology company’s stock worth $68,906,000 after acquiring an additional 560,110 shares in the last quarter. Finally, Capital Guardian Trust Co. grew its stake in shares of Seattle Genetics by 82.2% in the 3rd quarter. Capital Guardian Trust Co. now owns 1,064,300 shares of the biotechnology company’s stock worth $57,909,000 after acquiring an additional 480,044 shares in the last quarter. Hedge funds and other institutional investors own 98.89% of the company’s stock.

SGEN has been the topic of several research reports. Cantor Fitzgerald set a $46.00 price objective on shares of Seattle Genetics and gave the stock a “hold” rating in a report on Monday, October 2nd. SunTrust Banks restated a “hold” rating and set a $45.00 price objective on shares of Seattle Genetics in a report on Wednesday, October 4th. Goldman Sachs Group restated a “neutral” rating and set a $64.00 price objective on shares of Seattle Genetics in a report on Friday, October 6th. Zacks Investment Research upgraded shares of Seattle Genetics from a “hold” rating to a “buy” rating and set a $64.00 price objective on the stock in a report on Tuesday, October 10th. Finally, Oppenheimer initiated coverage on shares of Seattle Genetics in a report on Tuesday, October 10th. They set a “hold” rating on the stock. One investment analyst has rated the stock with a sell rating, twelve have given a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the stock. Seattle Genetics has a consensus rating of “Hold” and an average target price of $63.76.

ILLEGAL ACTIVITY NOTICE: “Seattle Genetics, Inc. (SGEN) Insider Clay B. Siegall Sells 18,832 Shares” was originally posted by American Banking News and is the property of of American Banking News. If you are reading this story on another website, it was illegally stolen and republished in violation of US and international copyright laws. The legal version of this story can be accessed at https://www.americanbankingnews.com/2018/01/16/seattle-genetics-inc-sgen-insider-clay-b-siegall-sells-18832-shares.html.

Seattle Genetics Company Profile

Seattle Genetics, Inc is a biotechnology company focused on the development and commercialization of therapies for the treatment of cancer. The Company is engaged in the development and sale of pharmaceutical products on its own behalf or in collaboration with others. The Company’s marketed product ADCETRIS, or brentuximab vedotin, is an antibody-drug conjugate (ADC).

Insider Buying and Selling by Quarter for Seattle Genetics (NASDAQ:SGEN)

Receive News & Ratings for Seattle Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seattle Genetics and related companies with MarketBeat.com's FREE daily email newsletter.